Literature DB >> 18829991

Late outcomes after drug-eluting stent implantation in "real-world" clinical practice.

David R Ramsdale1, Archana Rao, Omar Asghar, Kathryn A Ramsdale, Ewan McKay.   

Abstract

BACKGROUND: We report the late outcomes in 411 consecutive patients undergoing drug-eluting stent (DES) implantation by a single operator between 2003-2006.
METHODS: Prospective registry with continuous follow up. Patients with stable angina (SA) or acute coronary syndrome (ACS) received DES for long lesions, small vessels, chronic total occlusion, bifurcation, aorto-ostial, left main, post atherectomy or saphenous vein graft lesions, multivessel/multilesion single-vessel (V) disease, in-stent restenosis (ISR) or diabetes.
RESULTS: Age range: 34-86 years. One hundred sixty-six (40.3%) had ACS, 98.3% hypercholesterolemia and 14.6% diabetes. Two hundred sixty-one (63.5%) had percutaneous coronary intervention (PCI) to 1V and 150 (36.5%) to >1V. Six hundred seven V were treated. Two hundred fifty-nine patients (63%) had multilesion PCI, and 109 (26.5%) 1V multilesion PCI. Two hundred ninety-three (71.3%) patients had long lesions and 224 had Vs < 2.75 mm diameter. 75.5% of lesions were Type B2/C. 1-8 stents were implanted/patient. Eight hundred twenty-two of 883 stents were DES. One hundred eight patients received > or = 1 stent of < or = 2.5 mm diameter and 246 patients received stents greater than or equal to 20 mm long. Twenty-five patients developed late complications. ISR occurred in 23, 3.5-38 months after DES implantation. Three had sudden late DES thrombosis (LST). One-third also had ISR. Twenty of twenty-five required PCI, 1 CABG and 4 medical treatment. Subsequently, 3 of the 20 required further PCI for recurrent ISR and 1 CABG. 9 patients died during 1-5-year follow up.
CONCLUSIONS: In "real-world" patients at increased risk of ISR after bare-metal stenting (BMS), "off-label" DES implantation has a low incidence of late complications. The most common is ISR which presents later than after BMS. Acute LST is serious but unusual and may be accompanied by ISR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829991

Source DB:  PubMed          Journal:  J Invasive Cardiol        ISSN: 1042-3931            Impact factor:   2.022


  6 in total

1.  Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: results from the German DES.DE-Registry.

Authors:  Timm Bauer; Christoph A Nienaber; Ibrahim Akin; Karl-Heinz Kuck; Matthias Hochadel; Jochen Senges; Thomas Fetsch; Ulrich Tebbe; Stefan N Willich; Jürgen Stumpf; Georg V Sabin; Sigmund Silber; Gert Richardt; Ralf Zahn
Journal:  Clin Res Cardiol       Date:  2011-03-18       Impact factor: 5.460

2.  Recurrent angina after coronary angioplasty: mechanisms, diagnostic and therapeutic options.

Authors:  Paolo Izzo; Andrea Macchi; Luisa De Gennaro; Antonio Gaglione; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-06

3.  Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?

Authors:  Vasilios G Athyros; Thomas D Gossios; Konstantinos Tziomalos; Matilda Florentin; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2011-12-30       Impact factor: 3.318

4.  Safety and effectiveness of drug-eluting stents in Chinese patients with coronary artery disease with off- and on-label indications: results from a single-centre registry.

Authors:  Xu-Min Hou; Wen-Zheng Han; Xing-Biao Qiu; Hui Chen; Wei-Yi Fang
Journal:  Heart Asia       Date:  2013-01-24

5.  New stent design for use in small coronary arteries during percutaneous coronary intervention.

Authors:  Juan F Granada; Barbara A Huibregtse; Keith D Dawkins
Journal:  Med Devices (Auckl)       Date:  2010-10-19

6.  Chest pain after percutaneous coronary intervention in patients with stable angina.

Authors:  Chao-Chien Chang; Yueh-Chung Chen; Eng-Thiam Ong; Wei-Cheng Chen; Chia-Hsiu Chang; Kuan-Jen Chen; Cheng-Wen Chiang
Journal:  Clin Interv Aging       Date:  2016-08-18       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.